Sarepta Therapeutics Announces FDA Approval Of ELEVIDYS, First Gene Therapy To Treat Duchenne Muscular Dystrophy
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics has received FDA approval for ELEVIDYS, the first gene therapy to treat Duchenne Muscular Dystrophy. The one-time treatment is approved for ambulatory pediatric patients aged 4-5 years. Sarepta will host a conference call on June 22 at 4:30 p.m. ET.
June 22, 2023 | 6:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sarepta Therapeutics' FDA approval of ELEVIDYS, the first gene therapy for Duchenne Muscular Dystrophy, may positively impact its stock price.
The FDA approval of ELEVIDYS is a significant milestone for Sarepta Therapeutics, as it is the first gene therapy for Duchenne Muscular Dystrophy. This approval may lead to increased demand for the treatment, resulting in higher revenues and a potential positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100